{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:18:13Z","timestamp":1778617093419,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients with myelofibrosis (MF) experience debilitating symptoms that negatively impact health-related quality of life and functioning. The Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) is a 7-item questionnaire assessing the burden of MF symptoms, including fatigue, night sweats, pruritus, abdominal discomfort, pain under the left ribs, early satiety, and bone pain. This study evaluated the content validity of the MFSAF v4.0 in Janus kinase (JAK) inhibitor\u2013experienced participants with MF. Qualitative interviews were conducted with 20 symptomatic (MFSAF Total Symptom Score\u2009\u2265\u200910) participants from the US (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20095) and UK, Germany, Italy, Poland, and Spain (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093 each). The interviews began with concept elicitation to allow patients to spontaneously report important symptoms. Next, content validation determined if the MFSAF v4.0 items and numeric rating scale (NRS) were relevant, important, and understandable. Overall, participants showed a clear understanding of the MFSAF v4.0, and no more than 3 (15%) mentioned that a given item was not relevant to their experience. Participants consistently felt that it was easy to select an answer on the NRS and often indicated that an improvement of 2 to 4 points was meaningful. These findings support the MFSAF v4.0 as a content-valid measure of selected disease-related symptoms for patients with JAK inhibitor\u2013experienced MF.\n                  <\/jats:p>","DOI":"10.1186\/s41687-026-01047-8","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:16:56Z","timestamp":1774973816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Content validation of the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) in Janus kinase inhibitor\u2013experienced patients with myelofibrosis"],"prefix":"10.1186","volume":"10","author":[{"given":"Katelyn","family":"Cutts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Cardellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelesitse","family":"Phiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Gelhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"12","key":"1047_CR1","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/ajh.25230","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi A (2018) Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 93(12):1551\u20131560. https:\/\/doi.org\/10.1002\/ajh.25230","journal-title":"Am J Hematol"},{"key":"1047_CR2","doi-asserted-by":"publisher","unstructured":"Mesa RA, Harrison C, Palmer JM, Gupta V, McLornan DP, McMullin MF et al. (2023) Patient-reported outcomes and quality of life in anemic and symptomatic patients with myelofibrosis: results from the MOMENTUM study. Hemasphere 7(11):e966. https:\/\/doi.org\/10.1097\/hs9.0000000000000966","DOI":"10.1097\/hs9.0000000000000966"},{"issue":"2","key":"1047_CR3","first-page":"121","volume":"16","author":"JM O\u2019Sullivan","year":"2018","unstructured":"O\u2019Sullivan JM, Harrison CN (2018) Myelofibrosis: clinicopathologic features, prognosis, and management. Clin Adv Hematol Oncol 16(2):121\u2013131","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"1047_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cncr.22365","volume":"109","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S et al. (2007) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer 109(1):68\u201376. https:\/\/doi.org\/10.1002\/cncr.22365","journal-title":"Cancer"},{"issue":"12","key":"1047_CR5","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/cncr.35244","volume":"130","author":"CN Harrison","year":"2024","unstructured":"Harrison CN, Kiladjian JJ, Koschmieder S, Passamonti F (2024) Myelofibrosis: current unmet needs, emerging treatments, and future perspectives. Cancer 130(12):2091\u20132097. https:\/\/doi.org\/10.1002\/cncr.35244","journal-title":"Cancer"},{"issue":"9","key":"1047_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787\u2013798. https:\/\/doi.org\/10.1056\/NEJMoa1110556","journal-title":"N Engl J Med"},{"key":"1047_CR7","doi-asserted-by":"publisher","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","DOI":"10.1056\/NEJMoa1110557"},{"issue":"5","key":"1047_CR8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D et al. (2015) Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol 1(5):643\u2013651. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1590","journal-title":"JAMA Oncol"},{"key":"1047_CR9","doi-asserted-by":"publisher","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P et al. (2017) Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 4(7):e317\u2013e324. https:\/\/doi.org\/10.1016\/s2352-3026(17)30088-1","DOI":"10.1016\/s2352-3026(17)30088-1"},{"issue":"5","key":"1047_CR10","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","volume":"4","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V et al. (2018) Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol 4(5):652\u2013659. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5818","journal-title":"JAMA Oncol"},{"key":"1047_CR11","doi-asserted-by":"publisher","unstructured":"Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A et al. (2017) Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol 4(5):e225\u2013e236. https:\/\/doi.org\/10.1016\/s2352-3026(17)30027-3","DOI":"10.1016\/s2352-3026(17)30027-3"},{"issue":"34","key":"1047_CR12","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/jco.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A et al. (2017) SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-na\u00efve patients with myelofibrosis. J Clin Oncol 35(34):3844\u20133850. https:\/\/doi.org\/10.1200\/jco.2017.73.4418","journal-title":"J Clin Oncol"},{"key":"1047_CR13","doi-asserted-by":"publisher","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D et al. (2018) Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol 5(2):e73\u2013e81. https:\/\/doi.org\/10.1016\/s2352-3026(17)30237-5","DOI":"10.1016\/s2352-3026(17)30237-5"},{"issue":"10373","key":"1047_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/s0140-6736(22)02036-0","volume":"401","author":"GAT Verstovsek","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT et al. (2023) Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 401(10373):269\u2013280. https:\/\/doi.org\/10.1016\/s0140-6736(22)02036-0","journal-title":"Lancet"},{"key":"1047_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.leukres.2017.05.012","volume":"59","author":"C Gwaltney","year":"2017","unstructured":"Gwaltney C, Paty J, Kwitkowski VE, Mesa RA, Dueck AC, Papadopoulos EJ et al. (2017) Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials. Leuk Res 59:26\u201331. https:\/\/doi.org\/10.1016\/j.leukres.2017.05.012","journal-title":"Leuk Res"},{"key":"1047_CR16","doi-asserted-by":"publisher","unstructured":"Papadopoulos EJ, Chopra AS, Howerter A, Cheng R, Doll H, Dave S et al. (2023) MPN-435 Qualitative and psychometric validation of Myelofibrosis Symptom Assessment Form version 4.0: a harmonized patient-reported outcome measure. Clin Lymphoma Myeloma Leuk 23:S395. https:\/\/doi.org\/10.1016\/S2152-2650(23)01243-0","DOI":"10.1016\/S2152-2650(23)01243-0"},{"key":"1047_CR17","doi-asserted-by":"publisher","unstructured":"Daskalopoulou C, Gorsh B, Dumi G, Deheshi S, Gwaltney C, Paty J et al. (2024) Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0: measurement properties from the MOMENTUM phase 3 study. Qual Life Res 34(3):739\u2013750. https:\/\/doi.org\/10.1007\/s11136-024-03855-1","DOI":"10.1007\/s11136-024-03855-1"},{"key":"1047_CR18","unstructured":"US Food and Drug Administration (2022) Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments: draft guidance. https:\/\/www.fda.gov\/media\/159516\/download. Accessed September 13, 2024"},{"key":"1047_CR19","unstructured":"US Food and Drug Administration (2022) Patient-focused drug development: methods to identify what is important to patients. https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4247. Accessed September 13, 2024"},{"key":"1047_CR20","unstructured":"ATLAS.Ti scientific software development GmbH. Qualitative data analysis software. https:\/\/atlasti.com. Accessed September 13, 2024"},{"key":"1047_CR21","doi-asserted-by":"publisher","DOI":"10.4135\/9781412983655","volume-title":"Cognitive interviewing: a tool for improving questionnaire design","author":"GB Willis","year":"2005","unstructured":"Willis GB (2005) Cognitive interviewing: a tool for improving questionnaire design. Sage Publications, Thousand Oaks, CA"},{"issue":"5","key":"1047_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2165\/00019053-200826050-00002","volume":"26","author":"NK Leidy","year":"2008","unstructured":"Leidy NK, Vernon M (2008) Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics 26(5):363\u2013370. https:\/\/doi.org\/10.2165\/00019053-200826050-00002","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"1047_CR23","doi-asserted-by":"publisher","first-page":"10612","DOI":"10.1002\/cam4.5799","volume":"12","author":"RA Mesa","year":"2023","unstructured":"Mesa RA, Hudgens S, Floden L, Harrison CN, Palmer J, Gupta V et al. (2023) Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies. Cancer Med 12(9):10612\u201310624. https:\/\/doi.org\/10.1002\/cam4.5799","journal-title":"Cancer Med"},{"issue":"1","key":"1047_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R et al. (2012) One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 87(1):25\u201333. https:\/\/doi.org\/10.1016\/j.mayocp.2011.11.001","journal-title":"Mayo Clin Proc"},{"issue":"16_suppl","key":"1047_CR25","doi-asserted-by":"publisher","first-page":"7066","DOI":"10.1200\/JCO.2023.41.16_suppl.7066","volume":"41","author":"RA Mesa","year":"2023","unstructured":"Mesa RA, Palandri F, Verstovsek S, Masarova L, Harrison C, Mazerolle F et al. (2023) Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2). J Clin Oncol 41(16_suppl):7066\u20137066. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.7066","journal-title":"J Clin Oncol"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-01047-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01047-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01047-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:43:41Z","timestamp":1778615021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-01047-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1047"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-01047-8","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by a central ethics committee, Salus IRB, prior to conducting any study-related activities. Only participants who provided consent were enrolled. All data collected in this study were strictly confidential, in accordance with relevant laws and regulations of the countries where the study was being conducted, as appropriate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KC and HG report employment with Evidera, a business unit of Thermo Fisher, which was contracted to conduct this study by GSK. AC, SZ, and KP report employment with and stock\/stock options in GSK.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}